MIAMI, Jan. 23, 2021 /PRNewswire/ -- eMed™, a
digital health company democratizing healthcare through digital
point-of-care solutions, announced it will begin to
administer the FDA-authorized, at-home symptomatic BinaxNOW™
COVID-19 Ag Card rapid home test to
100,000 qualified individuals across the U.S. who order through
eMed.com beginning today. These 100,000 individuals will be
among the first to use eMed's transformative approach to at-home
testing.
At $25 each, the eMed-administered
rapid tests are the first virtually guided, at-home tests
available and the most affordable testing option on the market with
authenticated results automatically reported to public health
authorities.
"We are thrilled to share with the public the eMed digital
health platform is coming to the market in just over a month since
receiving FDA authorization for truly at-home COVID-19 rapid
testing," said Dr. Patrice Harris,
eMed CEO. "Our team has been working tirelessly to put tests in the
hands of people across our nation, starting with large employers
and states. Today's announcement is the first step in ensuring the
general public also has access to affordable, at-home testing."
During a time when COVID-19 testing is needed most, consumers
will no longer have to rush to COVID-19 testing sites between daily
appointments and tasks, nor will they have to wait in long
lines for testing, risking potential exposure to the
coronavirus.
Instead, with the instruction and verification by an eMed
Certified Guide, they can be among the first 100,000 users to
receive reliable and certified results from the convenience of
their home in just 15 minutes.
Users can access eMed from their desktop computer or laptop
with an internet connection, and have confidence in their
authenticated, at-home rapid testing experience by following the
onscreen instructions at www.eMed.com.
"At eMed, we are democratizing healthcare and providing greater
access to testing," said Dr. Harris. "Every day I am inspired by
the opportunity to improve health outcomes of individuals and
communities through the work we do day-in and day-out. Widespread,
accessible testing for all is an important key to help get back to
life together."
eMed expects to distribute and administer 30 million tests in Q1
of 2021 and an additional 90 million tests in Q2.
eMed's digital point-of-care solutions include prescriptions,
test distribution, user authentication, guided test-taking with
assistance from eMed Certified Guides, and automated and secure
reporting.
About eMed
eMed (www.eMed.com) is a digital health
company democratizing healthcare with a digital point-of-care
platform that provides fast, easy and affordable at-home healthcare
testing, supervised and guided online by eMed Certified Guides. We
embrace quantitative medicine to deliver prescribed tests and
treatments directly to patients, driving better and more
cost-effective health outcomes.
- This product has not been FDA cleared or approved; but has
been authorized by FDA under an EUA;
- This product has been authorized only for the detection of
proteins from SARS- CoV-2, not for any other viruses or pathogens;
and,
- This product is only authorized for the duration of the
declaration that circumstances exist justifying the authorization
of emergency use of in vitro diagnostics for detection and/or
diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food,
Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the
declaration is terminated or authorization is revoked
sooner.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/digital-health-company-emed-launches-at-home-covid-19-rapid-testing-301213552.html
SOURCE eMed